1791 – Dinutuximab beta for primary relapse and refractory high-risk neuroblastoma

Recordati Rare Diseases Australia Pty Ltd

Change to existing listing – highly specialised therapies – National Health Reform Agreement Addendum.

Dinutuximab beta (monoclonal antibody therapy) used in conjunction with combination chemotherapy in patients who have experienced a primary relapse or are refractory to treatment. This treatment is currently funded for patients who achieve at least a partial response to induction chemotherapy and this application is seeking an extension of funding to include the primary relapse or refractory population.

Type: Therapeutic technology

Neuroblastoma is the most frequent cancer in children less than one year old. About half of patients with neuroblastoma are classified as having high-risk disease. The treatment is intended for patients with high-risk neuroblastoma who experience primary (first) relapse or are refractory (do not respond) to treatment.

Provide your input online

The following consultation deadlines apply:

• Pre-PASC consultation deadline: Bypassing PASC
• Pre-MSAC consultation deadline: Friday 14 February 2025 11:59 pm AEDT

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: Bypassing PASC
• ESC meeting: 13 to 14 February 2025
• MSAC meeting: 3 to 4 April 2025

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.